4′-bis(2-bromoacetyl)biphenyl_Kain Industrial Additive

Background and overview[1] 4,4’-Bis(2-bromoacetyl)biphenyl is a key intermediate in the synthesis of the anti-hepatitis C drug daclatasvir. Daclatasvir is a new hepatitis C drug developed by Bristol-Myers Squibb in the United States. On July 24, 2015, the U.S. FDA approved it for the treatment of chronic hepatitis C. The trade name is Daklinza. It is…